UBS Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

UBS Group’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,000	Closed	-$826K	–	10349
2023 Q2	$826K	Buy	+21,000	New	+$741K	﹤0.01%	4406
2017 Q1	–	Sell	-4,400	Closed	-$21K	–	8094
2016 Q4	$21K	Buy	+4,400	New	+$131K	﹤0.01%	6491
2015 Q3	–	Sell	-50,000	Closed	-$2.6M	–	8720
2015 Q2	$2.6M	Buy	+50,000	New	+$2.49M	﹤0.01%	2724

UBS Group's ISEE Position: Q3 2023 in Review

UBS Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 10,431 shares — an estimated $410K sold.

UBS Group first reported a position in ISEE in Q4 2014 and held it in 35 quarters. The position peaked at $5.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

UBS Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 10,431 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $410K.
UBS Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2014 and held it in 35 quarters.
UBS Group's IVERIC bio, Inc. Common Stock position peaked at $5.79M in Q4 2022.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.